Tags : Monoclonal Antibody

OncoOne Entered into an Agreement with GenScript ProBio for the

Tuba Khan November 18, 2021

Shots: The companies collaborated to develop cell line, drug substance, and drug product manufacturing of therapeutic and diagnostic mAbs directed against the immuno-oncology target oxMIF for the treatment of multiple […]readmore

Clinical Trials

Merck Signs a Clinical Trial Collaboration with Xilio for Anti-CTLA-4

Tuba Khan May 25, 2021

Shots: The companies collaborated to evaluate XTX101 + Keytruda for patients with solid tumors. The planned P-I study will be conducted by Xilio and is designed to evaluate the safety […]readmore

Tags : Monoclonal Antibody

OncoOne Entered into an Agreement with GenScript ProBio for the

Merck Signs a Clinical Trial Collaboration with Xilio for Anti-CTLA-4

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Monoclonal Antibody

OncoOne Entered into an Agreement with GenScript ProBio for the

Merck Signs a Clinical Trial Collaboration with Xilio for Anti-CTLA-4

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company